- Report
- May 2024
- 170 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- March 2025
- 150 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 145 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 143 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 140 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- January 2025
- 142 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- December 2024
- 144 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- December 2024
- 132 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- December 2024
- 140 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- December 2024
- 142 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- December 2024
- 145 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- May 2024
- 124 Pages
Global
From €3618EUR$3,950USD£3,075GBP
- Report
- April 2025
- 183 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- April 2025
- 182 Pages
Global
From €4122EUR$4,500USD£3,504GBP
- Report
- April 2025
- 180 Pages
Global
From €4122EUR$4,500USD£3,504GBP

The Drugs by Therapeutic Area market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs for specific medical conditions. These drugs are designed to treat a wide range of diseases, from cancer to mental health disorders. Companies in this market typically specialize in one or more therapeutic areas, such as oncology, neurology, or cardiology. They develop drugs that target specific medical conditions and then market them to healthcare providers and patients. Companies in this market include Pfizer, Merck, Novartis, GlaxoSmithKline, and Sanofi. Show Less Read more